EPI vs IBB
WisdomTree India Earnings Fund vs iShares Biotechnology ETF
- • IBB has the lower expense ratio at 0.44% vs 0.84% for EPI.
- • IBB pays a higher dividend yield (0.16%).
Side-by-side metrics
| Metric | EPI | IBB |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.84% | 0.44% |
Dividend yield Trailing 12-month yield. | 0.00% | 0.16% |
AUM Assets under management — bigger funds are typically more liquid. | $1.78B | $11.50B |
YTD return | -4.97% | 30.22% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.67 | 0.60 |
P/E ratio | 18.92 | 25.48 |
Last price | $44.26 | $217.75 |
Inception | — | — |
Issuer | WisdomTree | iShares |
EPI top holdings
| RELIANCE.NS | Reliance Industries Ltd | 0.69% |
| HINDPETRO.NS | Hindustan Petroleum Corp Ltd | 0.57% |
| ICICIBANK.NS | ICICI Bank Ltd | 0.55% |
| POWERGRID.BO | Power Grid Corp Of India Ltd | 0.52% |
| NTPC.BO | NTPC Ltd | 0.51% |
| HDFCBANK.NS | HDFC Bank Ltd | 0.51% |
| LT.NS | Larsen & Toubro Ltd | 0.46% |
IBB top holdings
| GILD | Gilead Sciences Inc | 8.94% |
| AMGN | Amgen Inc | 8.31% |
| VRTX | Vertex Pharmaceuticals Inc | 7.87% |
| REGN | Regeneron Pharmaceuticals Inc | 6.24% |
| MRNA | Moderna Inc | 5.49% |
| NTRA | Natera Inc | 3.78% |
| ARGX | argenx SE ADR | 3.36% |
| BIIB | Biogen Inc | 2.52% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 2.50% |
| ILMN | Illumina Inc | 2.41% |
About EPI
EPI (WisdomTree India Earnings Fund) is Indian companies weighted by earnings. Managed by WisdomTree, the fund carries $1.8B in assets under management, an expense ratio of 0.84%. Its largest holding is Reliance Industries Ltd (RELIANCE.NS), which represents 0.7% of the portfolio. Real Estate is the fund's largest sector exposure at 0.9%.
About IBB
IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $11.5B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.16%. Its largest holding is Gilead Sciences Inc (GILD), which represents 8.9% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.